Global Fluid Biopsy Market Report 2019-2024 - Major Players are Bio-Rad Labs, LungLife AI (Cynvenio), Guardant Health, Horizon Discovery, and Qiagen -

DUBLIN--()--The "Fluid Biopsy Market - Growth, Trends, and Forecast (2019-2024)" report has been added to's offering.

Key Market Trends

Breast Cancer is Expected to Grow with a High CAGR

Breast cancer is the most common cancer among women and is the leading cause of mortality. It accounts for 12% of new cases of cancer being diagnosed every year. Incidence rates vary greatly worldwide. It is increasing, particularly in the developing countries, where a majority of the cases are diagnosed at later stages. Breast cancer is the most commonly diagnosed cancer among American women. About 1 in 8 American women develop invasive breast cancer, over the course of her lifetime. In 2016, an estimated 246,660 new cases of invasive breast cancer and 61,000 new cases of non-invasive (in situ) breast cancer were expected to be diagnosed among women in the United States.

Breast cancer is hormone related. Reproductive factors associated with prolonged exposure to endogenous estrogens, such as early menarche, late menopause, late age at first childbirth, etc. are among the most important risk factors for breast cancer. About 21% of all breast cancer deaths worldwide can be attributed to lifestyle factors, such as alcohol use, obesity, and physical inactivity.

Early detection and treatment reduce the mortality rate. A biopsy is the only diagnostic procedure that can definitely determine if the suspicious area is cancerous. Breast biopsy test removes tissue or sometimes fluid from the suspicious area, and the removed cells are examined under a microscope and further tested, to check for the presence of breast cancer. Liquid biopsies are a reliable alternative to conventional biopsies, offering a potentially cheaper, easier, and less invasive way of monitoring malignancies.

Patients can be tested more frequently. This method provides accurate results, as genetic sequencing of free-floating tumor DNA captures the diversity of genetic alterations found in cancer cells, in different parts of the body, including the primary tumor and metastases. Liquid biopsies could be used to guide cancer treatment decisions. Therefore, these tests are gaining traction, within the diagnostic industry.

The fluid biopsy market is expected to boom and the increasing incidences of breast cancer is one of the driving factors for the growth. The various liquid biopsy platforms (circulating tumor cells (CTCs), and cell-free DNA (cfDNA), and exosomes) have shown a potential of adding tremendous value towards the care of breast cancer patients. Colorectal cancer and breast cancer together hold the major share of the fluid biopsy market.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. In North America region, the United States holds the largest market share and this is due to the fact that the cancer is the second most common cause of death in the United States which has helped the growth of the Fluid Biopsy market in the country.

Competitive Landscape

The Fluid Biopsy market is competitive and consists of a few major players. In terms of market share, these major players currently dominate the market. Some of the major players of the market are Bio-Rad Laboratories, LungLife AI (Cynvenio), Guardant Health, Horizon Discovery, and Qiagen are among others.

Key Topics Covered





4.1 Market Overview

4.2 Market Drivers

4.2.1 Rising Demand for Non-Invasive Procedures

4.2.2 Increase in the Number of Cancer Cases being Reported Worldwide

4.3 Market Restraints

4.3.1 Growth of Alternative Technologies like Optical Biopsies

4.4 Porter's Five Force Analysis


5.1 By Indication

5.1.1 Lung Cancer

5.1.2 Breast Cancer

5.1.3 Colorectal

5.1.4 Others

5.2 By Type

5.2.1 Circulating Tumor Cells

5.2.2 Circulating Tumor DNA

5.2.3 Cell-Free DNA

5.3 Geography

5.3.1 North America US Canada Mexico

5.3.2 Europe Germany UK France Italy Spain Rest of Europe

5.3.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific

5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa

5.3.5 South America Brazil Argentina Rest of South America


6.1 Company Profiles

6.1.1 Bio-Rad Laboratories

6.1.2 LungLife AI Inc.

6.1.3 Inivata Ltd.

6.1.4 Diagnologix, LLC

6.1.5 Exosome Sciences Inc.

6.1.6 Grail Inc.

6.1.7 Guardant Health

6.1.8 Horizon Discovery

6.1.9 Illumina, Inc

6.1.10 Qiagen N.V.


For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: In Vitro Diagnostics

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: In Vitro Diagnostics